Cantor Fitzgerald Assumes Poseida Therapeutics, Inc (PSTX) at Overweight

Cantor Fitzgerald analyst Jennifer Kim assumes coverage on Poseida Therapeutics, Inc (NASDAQ: PSTX) with a Overweight rating and a price target of $24.00.

The analyst commented, "PSTX is a clinical-stage biopharmaceutical company that is developing next-generation cell and gene therapies designed to overcome the key limitations of current cell and gene therapies (e.g., cost/accessibility, safety/tolerability, potency/durability). We believe the key focuses for PSTX this year are on the company's two Phase 1 fully allogeneic (off-the-shelf) CAR-T candidates, P-BCMA-ALLO1 (relapsed/refractory multiple myeloma, r/r MM) and P-MUC1C-ALLO1 (solid tumors), with initial clinical data for each guided to 2H22."

For an analyst ratings summary and ratings history on Poseida Therapeutics, Inc click here. For more ratings news on Poseida Therapeutics, Inc click here.

Shares of Poseida Therapeutics, Inc closed at $1.87 yesterday.

You May Also Be Interested In

• Morgan Stanley Sees Slower Margin Expansion Lightspeed POS Inc. (LSPD) PT Lowered to $31
• Future PLC (FUTR:LN) PT Lowered to GBP27.50 at Barclays
• Indus Towers Ltd (INDUSTOW:IN) PT Lowered to INR350 at Deutsche Bank